Salazar R - Search Results

1

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.

Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H, Guillén-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, Del Pozo N, Martínez de Villarreal J, Real FX, Vidal N, Capella G, Alemany R, Blasi E, Blasco C, Cascalló M, Salazar R. Garcia-Carbonero R, et al. Among authors: salazar r. J Immunother Cancer. 2022 Mar;10(3):e003255. doi: 10.1136/jitc-2021-003255. J Immunother Cancer. 2022. PMID: 35338084 Free PMC article.

2

Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Montesinos J, Sola C, Maroto P, Salazar R, Balmaña J, Ramírez A, Pardo B, Pericás R, Gurgui M, López-López JJ. Montesinos J, et al. Among authors: salazar r. Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):569-72. doi: 10.1007/s100960100555. Eur J Clin Microbiol Infect Dis. 2001. PMID: 11681437

3

Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.

Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM. Pardo B, et al. Among authors: salazar r. Clin Cancer Res. 2008 Feb 15;14(4):1116-23. doi: 10.1158/1078-0432.CCR-07-4366. Clin Cancer Res. 2008. PMID: 18281545 Clinical Trial.

4

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.

Molleví DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, Ramos E, Figueras J, Capella G, Villanueva A. Molleví DG, et al. Among authors: salazar r. Br J Cancer. 2008 Nov 18;99(10):1718-25. doi: 10.1038/sj.bjc.6604747. Epub 2008 Oct 28. Br J Cancer. 2008. PMID: 19002188 Free PMC article.

5

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH. Salazar R, et al. Invest New Drugs. 2011 Dec;29(6):1406-13. doi: 10.1007/s10637-010-9488-1. Epub 2010 Jul 10. Invest New Drugs. 2011. PMID: 20623160 Clinical Trial.

6

A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors.

Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J. Vilar E, et al. Among authors: salazar r. Invest New Drugs. 2012 Feb;30(1):299-305. doi: 10.1007/s10637-010-9529-9. Epub 2010 Sep 7. Invest New Drugs. 2012. PMID: 20820909 Clinical Trial.

7

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS).

García-Carbonero R, Salazar R, Sevilla I, Isla D. García-Carbonero R, et al. Among authors: salazar r. Clin Transl Oncol. 2011 Aug;13(8):545-51. doi: 10.1007/s12094-011-0695-9. Clin Transl Oncol. 2011. PMID: 21821488

8

Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype.

Aytes A, Molleví DG, Martinez-Iniesta M, Nadal M, Vidal A, Morales A, Salazar R, Capellà G, Villanueva A. Aytes A, et al. Among authors: salazar r. Mol Carcinog. 2012 Sep;51(9):746-53. doi: 10.1002/mc.20843. Epub 2011 Aug 30. Mol Carcinog. 2012. PMID: 22125164

9

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.

Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J. Gómez-Martín C, et al. Among authors: salazar r. Invest New Drugs. 2013 Apr;31(2):390-8. doi: 10.1007/s10637-012-9830-x. Epub 2012 May 22. Invest New Drugs. 2013. PMID: 22615059 Clinical Trial.

10

Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature.

Salazar R, Cuadra C, Gil-Martín M, Vandermeeren A, Alfaro V, Coronado C. Salazar R, et al. Case Rep Oncol. 2012 May;5(2):354-8. doi: 10.1159/000341104. Epub 2012 Jul 5. Case Rep Oncol. 2012. PMID: 22807904 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

628 results

Search Page